Immune cell therapy shows promise in Hard-to-Treat lymphoma trial
NCT ID NCT05888493
First seen Nov 01, 2025 · Last updated Apr 23, 2026 · Updated 30 times
Summary
This phase 3 trial tests whether a one-time infusion of tisagenlecleucel (a CAR-T cell therapy) works better than standard treatments for adults with follicular lymphoma that has come back or not responded after at least two prior therapies. About 109 participants will be randomly assigned to receive either the cell therapy or usual care. The main goal is to see how long people live without their cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA (FL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Camperdown, New South Wales, 2050, Australia
-
Novartis Investigative Site
Clayton, Victoria, 3168, Australia
-
Novartis Investigative Site
Melbourne, Victoria, 3004, Australia
-
Novartis Investigative Site
Nedlands, Western Australia, 6009, Australia
-
Novartis Investigative Site
Salzburg, 5020, Austria
-
Novartis Investigative Site
Montreal, Quebec, H1T 2M4, Canada
-
Novartis Investigative Site
Ostrava, Poruba, 708 52, Czechia
-
Novartis Investigative Site
Budapest, H-1097, Hungary
-
Novartis Investigative Site
Poznan, Greater Poland Voivodeship, 60-355, Poland
-
Novartis Investigative Site
Gliwice, Silesian Voivodeship, 44-101, Poland
-
Novartis Investigative Site
Gdansk, 80-952, Poland
-
Novartis Investigative Site
Lodz, 93-513, Poland
-
Novartis Investigative Site
Singapore, 119074, Singapore
-
Novartis Investigative Site
Bratislava, 83310, Slovakia
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Seoul, 03722, South Korea
-
Novartis Investigative Site
Seoul, 05505, South Korea
-
Novartis Investigative Site
Seoul, 06351, South Korea
-
Novartis Investigative Site
Seoul, 06591, South Korea
-
Novartis Investigative Site
Santiago Compostela, A Coruna, 15706, Spain
-
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
-
Novartis Investigative Site
Santander, Cantabria, 39008, Spain
-
Novartis Investigative Site
El Palmar, Murcia, 30120, Spain
-
Novartis Investigative Site
Barcelona, 08035, Spain
-
Novartis Investigative Site
Córdoba, 14004, Spain
-
Novartis Investigative Site
Madrid, 28034, Spain
-
Novartis Investigative Site
Salamanca, 37007, Spain
-
Novartis Investigative Site
Kaohsiung City, 83301, Taiwan
-
Novartis Investigative Site
Taichung, 407219, Taiwan
-
Novartis Investigative Site
Taipei, 10002, Taiwan
Conditions
Explore the condition pages connected to this study.